Business Context and Reporting Period
Company: NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: A clinical-stage biopharmaceutical company developing novel drug delivery technologies for central nervous system diseases. Lead candidates include NEO100 (intranasal delivery for glioblastoma) and NEO212 (oral conjugate). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $39,990 |
| Net Loss | $(8,819,932) | $(32,326,016) |
| Loss Per Share (Basic & Diluted) | $(0.38) | $(1.78) |
| Operating Expenses | $7,055,662 | $31,940,832 |
| Cash and Cash Equivalents (End of Period) | $138,601 | $5,439,210 |
| Net Cash Used in Operating Activities | $(6,991,773) | $(5,650,055) |
| Net Cash Provided by Financing Activities | $7,071,645 | $11,024,372 |
| Total Assets | $3,330,161 | $2,823,634 |
| Total Liabilities | $16,561,326 | $20,331,363 |
| Stockholders' Deficit | $(13,231,165) | $(17,507,729) |
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by approximately $23.5 million compared to Q1 2025. This improvement is primarily driven by a $14.7 million decrease in stock-based compensation and a $10.4 million decrease in advisory fees, both of which were heavily impacted by one-time listing-related expenses in Q1 2025.
- Revenue: Revenue dropped to zero from $39,990 in the prior year, as the company did not generate fees from its "right to try" humanitarian program in the current quarter.
- Debt Repayment: The company repaid $6.67 million in convertible promissory notes in January 2026, eliminating this liability from the balance sheet.
- Financing Activity: The company raised approximately $13.1 million through a Private Investment in Public Equity (PIPE) financing and $0.66 million via an equity line of credit, offsetting the debt repayment and operating burn.
- Related Party Liabilities: Accrued advisory fees to a related party were paid down from $1.76 million to zero during the quarter.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. Cash on hand ($138,601) is insufficient to fund operations for the next 12 months without additional financing.
- Liquidity Strategy: The company is actively pursuing additional capital through a $16 million PIPE facility (partially closed), a $50 million equity purchase agreement with Mast Hill Fund, and a $10 million line of credit with HCWG. An S-3 registration statement was declared effective in April 2026, enabling an At-The-Market (ATM) offering of up to $75 million.
- Operational Progress: R&D expenses increased slightly ($288k) due to the addition of clinical trial sites for NEO100 and recruitment for NEO212. The company acquired a patent for 3D bioprinting technology in late 2025, now being amortized.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, including segregation of duties and related party transaction tracking. These weaknesses were not fully remediated as of March 31, 2026.
- Legal Contingencies: A litigation settlement payable of $4.3 million to Orient EuroPharma Co., Ltd. remains outstanding and unpaid. Another settlement with Fox Infused was paid in full in February 2026.
- Tax Withholding: The company has accrued $6.1 million in restricted stock tax withholding obligations that have not yet been remitted to taxing authorities, resulting in accrued penalties and interest.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $138,601 cash balance against the $7 million quarterly operating burn rate.
- Financing Execution: Confirm the status of the remaining $2.9 million commitment under the January 2026 PIPE and the utilization of the $50 million equity line of credit.
- Unpaid Liabilities: Assess the risk associated with the $4.3 million unpaid litigation settlement to Orient EuroPharma and the $6.1 million unremitted tax withholding obligation.
- Internal Controls: Review the remediation plan for material weaknesses in internal controls, specifically regarding related party transactions and financial reporting.
- Dilution Risk: Evaluate the impact of the ATM offering and ongoing equity issuances on existing shareholder dilution.